New approaches to antibody therapy

Area of Science:

• Oncology
• Immunotherapy
• Cancer Therapeutics

Background:

• Antibody-based therapies have achieved success in treating breast cancer and lymphoma.
• Solid tumors present challenges for antibody therapy due to delivery and effector function limitations.
• Targeting signaling pathways via antibodies against HER2/neu and EGFR has benefited epithelial malignancies.

Purpose of the Study:

• To review the role of antibodies in initiating anti-tumor immune responses.
• To discuss the application of antibodies as delivery vehicles for radionuclides in cancer treatment.

Main Methods:

• Literature review of antibody-based cancer therapies.
• Analysis of antibodies targeting signaling pathways and immune responses.
• Evaluation of antibody-mediated radionuclide delivery systems.

Main Results:

• Antibodies targeting extracellular domains like HER2/neu and EGFR show efficacy in epithelial cancers.
• Inducing anti-tumor inflammatory responses is a key goal for immunotherapy.
• Antibodies can be engineered to deliver cytotoxic payloads like radionuclides.

Conclusions:

• Antibody therapy is a powerful tool in oncology, with ongoing advancements for solid tumors.
• Future directions include enhancing immune responses and targeted delivery of therapeutic agents.
• Antibodies offer versatile strategies for cancer treatment, from direct signaling modulation to targeted payload delivery.